Novartis: Zandoz receives EU approval for biosimilar
(CercleFinance.com) - Novartis said that its Sandoz division has received approval from the European Commission for its biosimilar Ziextenzo, a generic version of Amgen's white blood cell booster Neulasta to help reduce the risk of infection during chemotherapy.
Ziextenzo is indicated to reduce the duration of neutropenia and incidence of febrile neutropenia in adult patients treated with chemotherapy, with the exception of chronic myeloid leukemia and myelodysplastic syndromes, Novartis said.
Ziextenzo is the eigth approved biosimilar medicine for Sandoz, with a total of five in the past 18 months, it added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Ziextenzo is indicated to reduce the duration of neutropenia and incidence of febrile neutropenia in adult patients treated with chemotherapy, with the exception of chronic myeloid leukemia and myelodysplastic syndromes, Novartis said.
Ziextenzo is the eigth approved biosimilar medicine for Sandoz, with a total of five in the past 18 months, it added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.